West Paces Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

West Paces Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$19K	Hold	25	–	–	﹤0.01%	359
2026 Q2	$15.6K	Buy	+25	New	+$17K	﹤0.01%	360
2025 Q2	–	Sell	-27	Closed	-$17.1K	–	482
2025 Q1	$17.1K	Hold	27	–	–	﹤0.01%	307
2024 Q4	$19.2K	Hold	27	–	–	﹤0.01%	306
2024 Q3	$28.4K	Hold	27	–	–	0.01%	280
2024 Q2	$28.4K	Hold	27	–	–	0.01%	268
2024 Q1	$26K	Buy	27 +23	+575%	+$21.9K	0.01%	287
2023 Q4	$3.51K	Buy	4 +2	+100%	+$1.65K	﹤0.01%	432
2023 Q3	$1.65K	Hold	2	–	–	﹤0.01%	436
2023 Q2	$1.44K	Sell	2 -1	-33%	-$771	﹤0.01%	468
2023 Q1	$2.46K	Buy	3 +1	+50%	+$754	﹤0.01%	457
2022 Q4	$1.44K	Hold	2	–	–	﹤0.01%	455
2022 Q3	$1.38K	Buy	+2	New	+$1.26K	﹤0.01%	452
2022 Q2	–	Sell	-2	Closed	-$1.4K	–	599
2022 Q1	$1.4K	Buy	+2	New	+$1.26K	﹤0.01%	507
2021 Q2	–	Sell	-40	Closed	-$18.9K	–	625
2021 Q1	$18.9K	Buy	+40	New	+$19.5K	0.01%	271
2017 Q1	–	Sell	-22	Closed	-$8.08K	–	537
2016 Q4	$8.08K	Buy	+22	New	+$8.37K	0.01%	360

Other funds holding REGN

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.22B AUM 4.07% 1-Year Est. Return

West Paces Advisors's REGN Position: Q3 2026 in Review

West Paces Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 25 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

West Paces Advisors first reported a position in REGN in Q4 2016 and has held it in 16 quarters since. The position peaked at $28.4K in Q3 2024. 704 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

West Paces Advisors held 25 shares of Regeneron Pharmaceuticals worth $19K as of Q3 2026.
West Paces Advisors left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of West Paces Advisors's portfolio in Q3 2026, its #359 holding.
West Paces Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 16 quarters since.
West Paces Advisors's Regeneron Pharmaceuticals position peaked at $28.4K in Q3 2024.
704 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on West Paces Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.